Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-02

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators have previously observed a reduced level of platelet aggregation 2 hours after healthy male individuals were asked to drink extra virgin olive oil (EVOO) that provided a higher level of one specific phenolic known as oleocanthal. This study will help the investigators further determine the effects of oleocanthal-rich EVOO intake on platelet function at 2, 4 and 6 hours after intake with food compared to platelet function in the morning after an overnight fast.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity

NCT02902913

Cardiovascular Diseases

COMPLETED NA

Cardioprotective Properties of Natural Anti-Platelet Activating Factor Extract From Winery By-products in Healthy Women

NCT04436263

Platelet Aggregation and Inflammation

UNKNOWN NA

Investigation of the Acute Effect of Novel Olive Oil on Postprandial Oxidative Stress Biomarkers (BioliveCT)

NCT05771571

Cardiometabolic Risk

COMPLETED NA

Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women

NCT03820336

Hypertension Vascular Stiffness

UNKNOWN NA

Nutritional Intervention With Table Olives in Healthy Volunteers

NCT03886597

Healthy Biological Availability Nutritional Intervention +2 more

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fifty adult male volunteers will be asked to participate in one of two study trials that will be randomized double-blind controlled crossover trials with 2 study visits. The participants will arrive to the facility after an overnight fast, and will be asked to consume their assigned EVOO either without (trial 1) or with (trial 2) a standardized low-phenolic food (such as rice, pasta or mashed potatoes) with 40 mL of one of 2 EVOOs that are matched for their total phenolic content, but with one oil containing oleocanthal, and one with very low levels of oleocanthal. At zero, two, 4 and 6 hours after EVOO intake a blood sample will be collected for the assessment of collagen- ADP-, and AA-induced platelet aggregation, as well as an untargeted metabolomics profile.

As an assessment of phenotypic stability, a subset of individuals (n=5 per trial) that have exhibit either low or high platelet responses, will be asked to repeat the above study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Aggregation Nutritional and Metabolic Disease Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

controlled, randomized, double-blind, with 2 interventions

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Extra Virgin Olive Oils will be stored and provided to the study investigators in coded single serving bottles

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oleocanthal-Rich Extra Virgin Olive Oil

Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil

Group Type EXPERIMENTAL

Oleocanthal-Rich Extra Virgin Olive Oil

Intervention Type OTHER

Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal

Oleocanthal-low Extra Virgin Olive Oil

Intervention Type OTHER

Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal

Oleocanthal-Low Extra Virgin Olive Oil

Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil

Group Type PLACEBO_COMPARATOR

Oleocanthal-Rich Extra Virgin Olive Oil

Intervention Type OTHER

Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal

Oleocanthal-low Extra Virgin Olive Oil

Intervention Type OTHER

Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oleocanthal-Rich Extra Virgin Olive Oil

Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal

Intervention Type OTHER

Oleocanthal-low Extra Virgin Olive Oil

Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Trials 1 and 2: Male; Trial 3: Male and Female
* 20-45 years old
* For females, a regular 25-30-day menstrual cycle
* Subject is willing and able to comply with the study protocols
* Subject is willing to drink 40 mL (approximately 2 tablespoons) of olive oil
* BMI 18.5 - 30 kg/m2
* Weight ≥ 110 pounds

Exclusion Criteria

* Adults who are not able to consent
* BMI ≥ 31 kg/m2
* Under current medical supervision
* 1 ug/ml and 3 ug/ml collagen screening maximal platelet aggregatory response of \< 65%.
* Platelet number or mean platelet values that are outside of the normal reference range as indicated on a complete blood cell count report from the UCD Med Center
* Current diagnosis of anemia; or a screening hemoglobin and hematocrit that is less than the normal reference range.
* Self-reported daily use of drugs that are known to affect platelet function, such as aspirin, Excedrin, and NSAIDS
* Females using hormonal contraception
* Ibuprofen intolerance or allergy
* Those with a bleeding disorder
* Non-English speaking
* Allergy to olives or olive oil
* Vegetarian, Vegan, food faddists, individuals using non-traditional diets, or on a weight loss diet.
* A history of cardiovascular disease, stroke, cancer, renal, hepatic, or thyroid disease, GI tract disorders, previous GI surgery
* Currently taking prescription drugs or supplements
* Indications of substance or alcohol abuse within the last 3 years
* Not willing to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements for six weeks prior to study enrollment.
* Not willing to refrain from olive oil consumption for 4 weeks prior to study enrollment, and throughout study enrollment
* Self-reported malabsorption (e.g. difficulty digesting or absorbing nutrients from food, potentially leading to bloating, cramping or gas)
* Current enrollee in a clinical research study.
* Individuals with blood clotting or platelet defect disorders

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes